<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006092</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-12395</org_study_id>
    <secondary_id>NCI-1230</secondary_id>
    <nct_id>NCT00006092</nct_id>
  </id_info>
  <brief_title>Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia</brief_title>
  <official_title>A Phase II Study of Arsenic Trioxide for Induction Therapy of Adult Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia and Previously Untreated Chronic Myeloid Leukemia With Blast Crisis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients&#xD;
      who have recurrent or refractory acute lymphoblastic leukemia or chronic myelogenous&#xD;
      leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the rate of clinical and hematologic response in patients with Philadelphia&#xD;
           chromosome-positive recurrent or refractory acute lymphoblastic leukemia or previously&#xD;
           untreated or recurrent or refractory blastic phase chronic myelogenous leukemia when&#xD;
           treated with arsenic trioxide.&#xD;
&#xD;
        -  Determine the duration of hematologic response and overall survival of these patients&#xD;
           when treated with this regimen.&#xD;
&#xD;
        -  Determine the pattern of clinical adverse experience in these patients when treated with&#xD;
           this regimen.&#xD;
&#xD;
        -  Determine the pharmacokinetic profile of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive arsenic trioxide IV over 2-3 hours daily for 28 days. Patients who respond&#xD;
      may receive a second course of therapy beginning 28 days from the last dose of the first&#xD;
      course.&#xD;
&#xD;
      Patients are followed monthly for 3 months, every 2 months for 6 months, and then every 3&#xD;
      months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24-49 patients will be accrued for this study within 2.5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual&#xD;
  </why_stopped>
  <start_date>August 2000</start_date>
  <completion_date type="Actual">March 2003</completion_date>
  <primary_completion_date type="Actual">March 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Rate of Response (ORR)</measure>
    <time_frame>2.5 years</time_frame>
    <description>Determine the rate of clinical and hematologic response in patients with Philadelphia chromosome-positive recurrent or refractory acute lymphoblastic leukemia or previously untreated or recurrent or refractory blastic phase chronic myelogenous leukemia when treated with arsenic trioxide.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Arsenic Trioxide Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive arsenic trioxide IV over 2-3 hours daily for 28 days. Patients who respond may receive a second course of therapy beginning 28 days from the last dose of the first course.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arsenic Trioxide</intervention_name>
    <arm_group_label>Arsenic Trioxide Treatment</arm_group_label>
    <other_name>Trisenox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of one of the following:&#xD;
&#xD;
               -  Acute lymphoblastic leukemia&#xD;
&#xD;
                    -  Philadelphia chromosome (Bcr-abl) positive&#xD;
&#xD;
                    -  Refractory to initial therapy OR recurrent following 1 induction therapy&#xD;
                       regimen with or without consolidation therapy and/or bone marrow&#xD;
                       transplantation&#xD;
&#xD;
               -  Blastic phase chronic myelogenous leukemia&#xD;
&#xD;
                    -  Philadelphia chromosome (Bcr-abl) positive&#xD;
&#xD;
                    -  Previously untreated OR recurrent or refractory following 1 induction&#xD;
                       therapy regimen with or without consolidation therapy including imatinib&#xD;
                       mesylate&#xD;
&#xD;
          -  Must not be eligible for bone marrow transplant&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 8 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST/ALT no greater than 2 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 times ULN&#xD;
&#xD;
          -  Creatinine clearance greater than 70 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No uncontrolled angina&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  No second degree heart block without pacemaker&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after study&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No uncontrolled infection or other serious concurrent illness&#xD;
&#xD;
          -  No peripheral neuropathy&#xD;
&#xD;
          -  No potassium less than 3.0 or greater than 5.5 mEq/L that can not be corrected OR&#xD;
&#xD;
          -  No magnesium less than 1.2 or greater than 2.5 mEq/L that can not be corrected&#xD;
&#xD;
          -  Electrolyte imbalances must be corrected prior to study entry&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 28 days since prior chemotherapy&#xD;
&#xD;
          -  At least 24 hours since prior hydroxyurea&#xD;
&#xD;
          -  No prior arsenic trioxide&#xD;
&#xD;
          -  No other concurrent cytotoxic chemotherapy except intrathecal chemotherapy for CNS&#xD;
             leukemia&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 28 days since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy including for palliation&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 14 days since prior imatinib mesylate&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent amphotericin B&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas P. Loughran, MD</last_name>
    <role>Study Chair</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>August 3, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 25, 2012</last_update_submitted>
  <last_update_submitted_qc>September 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>chronic myelogenous leukemia, BCR-ABL1 positive</keyword>
  <keyword>lymphoid leukemia</keyword>
  <keyword>myeloid and monocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arsenic Trioxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

